SecSonar.com

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Taysha Gene Therapies, Inc. (TSHA) is a Biotechnology company based in US with a market capitalization of $1.5B. Revenue grew 17.3% year-over-year and free cash flow was negative at -$93.8M. This page tracks TSHA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 73 employees · IPO Sep 24, 2020

Valuation

Valuation & price

$5.96 · as of May 17, 2026 · -14.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.96

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.98$4.66$2.34Jul 25Dec 25Jul 26Jul 7, 25$2.34Jul 9, 25$2.54Jul 11, 25$2.64Jul 15, 25$2.51Jul 17, 25$2.59Jul 21, 25$2.53Jul 23, 25$2.69Jul 25, 25$2.65Jul 29, 25$2.62Jul 31, 25$2.73Aug 4, 25$2.71Aug 6, 25$2.79Aug 11, 25$2.76Aug 13, 25$3.03Aug 15, 25$2.94Aug 19, 25$2.84Aug 21, 25$2.87Aug 25, 25$2.92Aug 27, 25$2.97Aug 29, 25$2.92Sep 3, 25$2.90Sep 5, 25$3.36Sep 9, 25$3.28Sep 11, 25$3.24Sep 16, 25$2.84Sep 18, 25$2.99Sep 22, 25$2.87Sep 24, 25$3.15Sep 26, 25$3.25Sep 30, 25$3.27Oct 2, 25$4.88Oct 6, 25$4.42Oct 8, 25$5.06Oct 10, 25$4.88Oct 14, 25$5.16Oct 16, 25$5.08Oct 21, 25$5.15Oct 23, 25$4.94Oct 27, 25$4.88Oct 29, 25$5.01Oct 31, 25$4.96Nov 4, 25$4.27Nov 6, 25$3.92Nov 10, 25$3.89Nov 12, 25$4.36Nov 14, 25$4.13Nov 18, 25$4.15Nov 20, 25$3.99Nov 25, 25$4.59Nov 28, 25$4.74Dec 2, 25$4.06Dec 4, 25$5.06Dec 8, 25$5.45Dec 10, 25$5.56Dec 12, 25$5.79Dec 16, 25$5.82Dec 18, 25$5.45Dec 22, 25$5.86Dec 24, 25$5.91Dec 29, 25$5.65Jan 2, 26$5.25Jan 6, 26$5.26Jan 8, 26$5.14Jan 12, 26$4.86Jan 14, 26$5.04Jan 16, 26$4.56Jan 21, 26$4.78Jan 23, 26$4.66Jan 27, 26$4.76Jan 29, 26$4.57Feb 2, 26$4.66Feb 4, 26$4.54Feb 9, 26$4.61Feb 11, 26$4.66Feb 13, 26$4.55Feb 18, 26$4.65Feb 20, 26$4.70Feb 24, 26$4.89Feb 26, 26$4.57Mar 2, 26$4.53Mar 4, 26$4.64Mar 6, 26$4.57Mar 10, 26$4.57Mar 12, 26$4.61Mar 17, 26$4.57Mar 19, 26$4.56Mar 23, 26$4.54Mar 25, 26$4.58Mar 27, 26$4.07Mar 31, 26$4.47Apr 2, 26$4.37Apr 7, 26$4.57Apr 9, 26$4.63Apr 13, 26$4.42Apr 15, 26$6.00Apr 17, 26$6.43Apr 22, 26$6.72Apr 24, 26$6.40Apr 28, 26$6.30Apr 30, 26$6.39May 4, 26$6.64May 6, 26$6.98May 8, 26$6.81May 12, 26$6.85May 14, 26$6.30May 18, 26$5.45May 20, 26$5.49May 22, 26$5.49May 28, 26$5.92Jun 1, 26$5.97Jun 3, 26$5.55Jun 5, 26$5.50Jun 9, 26$5.36Jun 11, 26$5.58Jun 15, 26$5.97Jun 17, 26$6.19Jun 22, 26$6.53Jun 24, 26$6.94Jun 26, 26$6.34Jul 2, 26$6.49
$2.3452-week range$6.98
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

17.3%

Revenue growth (YoY)

100.0%

Gross margin

-$93.8M

Free cash flow (USD)

-$301.6M

Net debt

Net cash position

27.8%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$2.5MFY 2023$15.5MFY 2024$8.3MFY 2025$9.8M
$0$9.8M

Free cash flow by year

2019 → 2025

FY 2019$135.0KFY 2020$-39.8MFY 2021$-138.6MFY 2022$-113.3MFY 2023$-80.4MFY 2024$-81.6MFY 2025$-93.8M
$135K-$93.8M

Gross margin by year

2022 → 2025

FY 20220.6%FY 2023100.0%FY 2024100.0%FY 2025100.0%
0.6%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCommon Stock OfferingJun 25, 2026Filing
  • 8-K eventRett Syndrome Program UpdateJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 2, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • Insider sellInsider Sell $892K · 10b5-1 PlanNagendran Sukumar · Director, President and Head of R&D · $892KApr 13, 2026Filing

Questions

Frequently asked questions

What is Taysha Gene Therapies, Inc.'s market cap?

Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.5B.

What is TSHA's P/E ratio?

A meaningful P/E ratio is not available for TSHA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TSHA's price-to-book (P/B) ratio?

TSHA trades at 5.96 times book value per share.

Are insiders buying TSHA stock?

SEC Form 4 filings show no open-market insider buys at Taysha Gene Therapies, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

MAZE

Maze Therapeutics, Inc.

$1.5B

IMCR

Immunocore Holdings plc

$1.5B

FTRE

Fortrea Holdings Inc.

$1.5B

ARDX

Ardelyx, Inc.

$1.5B

IOVA

Iovance Biotherapeutics, Inc.

$1.4B

INBX

Inhibrx Biosciences, Inc.

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.